Ambrx

Biopharma M&A activity jumped 71% in Q1 2024
Medical Marketing and Media
Thu, 05/16/24 - 11:37 am
M&A
Novo Nordisk
Catalent
Gilead Sciences
CymaBay Therapeutics
AstraZeneca
Fusion Pharmaceuticals
JNJ
Ambrx
7 Billion-Dollar Oncology M&As from Q1
BioSpace
Wed, 04/10/24 - 11:24 am
oncology
M&A
AbbVie
Immunogen
Bristol Myers Squibb
Mirati Therapeutics
RayzeBio
Novartis
MorphoSys
AstraZeneca
Fusion Pharmaceuticals
JNJ
Ambrx
Gracell
J&J to acquire ADC drug developer Ambrx for $2B
BioPharma Dive
Mon, 01/8/24 - 11:35 am
JNJ
Ambrx
M&A
antibody-drug conjugate
JPMHC 2024
ESMO: Ambrx's 'reset' arrives at the last line of prostate cancer, offering the kind of safety rarely seen
Fierce Biotech
Mon, 10/23/23 - 10:33 am
ESMO
Ambrx
prostate cancer
ARX517
antibody-drug conjugate
Biotech layoffs continue as Ambrx cuts staff and part of its pipeline to extend its cash
Endpoints
Wed, 10/19/22 - 10:40 am
Ambrx
layoffs
Uncertainty at Ambrx as biotech loses CEO, takes hard look at pipeline
Fierce Biotech
Wed, 08/17/22 - 11:01 am
Ambrx
Bristol Myers Squibb
antibody-drug conjugate
Another four IPOs complete busy week as biotech raise continues to match 2020's record pace
Endpoints
Fri, 06/18/21 - 10:06 am
IPOs
Lyell Immunopharma
Verve Therapeutics
Molecular Partners
ATAI Life Sciences
Century Therapeutics
Ambrx
Cyteir Therapeutics
FDA grants ARX788 fast track designation for HER2-positive metastatic breast cancer
Pharmaceutical Business Review
Tue, 01/5/21 - 09:57 am
Ambrx
FDA
ARX788
HER-2 postive breast cancer
fast tack
$200M investment to advance clinical programs for Ambrx
MedCity News
Mon, 11/23/20 - 10:18 pm
Ambrx
oncology
Astellas
BeiGene
Bristol-Myers Squibb
Following key late-stage advances, BeiGene puts down $10M to get some discovery projects rolling at Ambrx
Endpoints
Wed, 03/6/19 - 10:10 am
BeiGene
China
Ambrx
Chinese drugmakers snag antibody expert Ambrx in joint buyout
Fierce Biotech
Fri, 05/22/15 - 06:25 pm
China
Ambrx
M&A
Fosun Pharmaceutical
WuXi PharmaTech
Bristol-Myers' armed antibody partner Ambrx shoots for an $86M IPO
Fierce Biotech
Mon, 05/5/14 - 05:15 pm
IPOs
Bristol-Myers Squibb
Ambrx
China Biotech Week In Review: Pfizer's Attempt To Acquire AstraZeneca Could Run Into Trouble
Seeking Alpha
Sun, 05/4/14 - 11:44 am
Pfizer
AstraZeneca
Zhejiang Hisun Pharma
Ambrx
Sinovac Biotech
Hutchison MediPharma
TaiGen Biotechnology
WuXi PharmaTech
Concord Medical Services
Pulse of J.P. Morgan 2014: Interviews with 17 biopharma execs
Fierce Biotech
Fri, 01/17/14 - 05:54 pm
JPMHC 2014
Algeta
Macrogenics
Xencor
Acetylon
Enanta Pharmaceuticals
Clinigen
Iroko Pharmaceuticals
Protalix BioTherapeutics
Ambrx
Roche
Sialix
Verastem
pRED
Cubist Pharmaceuticals
Celgene
Otonomy
Lumena Pharmaceuticals
Merck in potential $300M research deal with Ambrx
Yahoo/AP
Mon, 06/18/12 - 10:53 am
Ambrx
Merck
R&D
Bristol-Myers Signs Deal
Yahoo/Zacks
Sat, 09/24/11 - 01:11 pm
Bristol-Myers Squibb
Ambrx
Fibroblast Growth Factor 21
FGF-21
Relaxin
diabetes
Bristol pays $24M for early-stage biotech drugs
Yahoo/AP
Thu, 09/22/11 - 05:32 pm
Bristol-Myers Squibb
Ambrx
Relaxin
fibroblast activation protein
Ambrx, Wyeth ink antibody dev. deal
Fierce Pharma
Fri, 09/18/09 - 10:58 am
Wyeth
Ambrx
antibody discovery
partnerships